Cx Precision Medicine is a life science company developing blood-based biomarker screening technology as well as companion diagnostics for therapeutic agents.

Our lead products are focused on neurodegenerative diseases such as Alzheimer´s disease, Parkinson´s disease, and other dementia-causing disorders.

Our low-cost and non-invasive test will rule out Alzheimer´s disease and Parkinson´s disease for many people and help identify others who will benefit from more comprehensive testing. Our test will also help physicians treat patients with the right medicines more quickly.

As the gatekeepers for our medical system, primary care providers need the ability to screen for diseases like Alzheimer’s and Parkinson’s in order to expedite treatment and provide each patient with peace of mind.

Evidence-based Precision Medicine

Cx Precision Medicine is focusing right now on Alzheimer’s disease and Parkinson’s to develop a novel plan that can simplify the diagnosis and treatment of these diseases. By taking the approach that Alzheimer’s, Parkinson’s and other dementia-causing disorders reflect many different pathologies, treatment can be targeted more precisely.

LEARN ABOUT OUR APPROACH

Expanded Vision

CxPM technology will be expanded across other neurodegeneraative diseases. Using biomarkers and targeted treatment, patients will be treated with the right drugs at the right time.

MEET THE CxPM TEAM